These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
275 related articles for article (PubMed ID: 31039059)
1. Adherence to Adjuvant Endocrine Therapy in Insured Black and White Breast Cancer Survivors: Exploring Adherence Measures in Patient Data. Sheppard VB; He J; Sutton A; Cromwell L; Adunlin G; Salgado TM; Tolsma D; Trout M; Robinson BE; Edmonds MC; Bosworth HB; Tadesse MG J Manag Care Spec Pharm; 2019 May; 25(5):578-586. PubMed ID: 31039059 [TBL] [Abstract][Full Text] [Related]
2. Factors Associated with Adherence to Adjuvant Endocrine Therapy Among Privately Insured and Newly Diagnosed Breast Cancer Patients: A Quantile Regression Analysis. Farias AJ; Hansen RN; Zeliadt SB; Ornelas IJ; Li CI; Thompson B J Manag Care Spec Pharm; 2016 Aug; 22(8):969-78. PubMed ID: 27459660 [TBL] [Abstract][Full Text] [Related]
3. Oral Endocrine Therapy Agent, Race/Ethnicity, and Time on Therapy Predict Adherence in Breast Cancer Patients in a Large Academic Institution. Hwang GS; Paranjpe R; Opsomer C; Lu K; Abajue U; Abughosh S; Zaghloul H; Trivedi MV Clin Breast Cancer; 2020 Dec; 20(6):520-526. PubMed ID: 32669209 [TBL] [Abstract][Full Text] [Related]
4. Evaluation of the Quality of Adjuvant Endocrine Therapy Delivery for Breast Cancer Care in the United States. Daly B; Olopade OI; Hou N; Yao K; Winchester DJ; Huo D JAMA Oncol; 2017 Jul; 3(7):928-935. PubMed ID: 28152150 [TBL] [Abstract][Full Text] [Related]
5. Initiation and adherence to adjuvant endocrine therapy among urban, insured American Indian/Alaska Native breast cancer survivors. Emerson MA; Achacoso NS; Benefield HC; Troester MA; Habel LA Cancer; 2021 Jun; 127(11):1847-1856. PubMed ID: 33620753 [TBL] [Abstract][Full Text] [Related]
6. Race and Patient-reported Symptoms in Adherence to Adjuvant Endocrine Therapy: A Report from the Women's Hormonal Initiation and Persistence Study. Sheppard VB; Sutton AL; Hurtado-de-Mendoza A; He J; Dahman B; Edmonds MC; Hackney MH; Tadesse MG Cancer Epidemiol Biomarkers Prev; 2021 Apr; 30(4):699-709. PubMed ID: 33514603 [TBL] [Abstract][Full Text] [Related]
7. Racial differences in long-term adjuvant endocrine therapy adherence and mortality among Medicaid-insured breast cancer patients in Texas: Findings from TCR-Medicaid linked data. Farias AJ; Wu WH; Du XL BMC Cancer; 2018 Dec; 18(1):1214. PubMed ID: 30514270 [TBL] [Abstract][Full Text] [Related]
8. Impact of patient race and geographical factors on initiation and adherence to adjuvant endocrine therapy in medicare breast cancer survivors. Camacho FT; Tan X; Alcalá HE; Shah S; Anderson RT; Balkrishnan R Medicine (Baltimore); 2017 Jun; 96(24):e7147. PubMed ID: 28614244 [TBL] [Abstract][Full Text] [Related]
9. Association Between Out-Of-Pocket Costs, Race/Ethnicity, and Adjuvant Endocrine Therapy Adherence Among Medicare Patients With Breast Cancer. Farias AJ; Du XL J Clin Oncol; 2017 Jan; 35(1):86-95. PubMed ID: 28034069 [TBL] [Abstract][Full Text] [Related]
10. Interventions to promote adherence to endocrine therapy among breast cancer survivors: A meta-analysis. Finitsis DJ; Vose BA; Mahalak JG; Salner AL Psychooncology; 2019 Feb; 28(2):255-263. PubMed ID: 30511789 [TBL] [Abstract][Full Text] [Related]
11. Racial Differences in Patient-Reported Symptoms and Adherence to Adjuvant Endocrine Therapy Among Women With Early-Stage, Hormone Receptor-Positive Breast Cancer. Hu X; Walker MS; Stepanski E; Kaplan CM; Martin MY; Vidal GA; Schwartzberg LS; Graetz I JAMA Netw Open; 2022 Aug; 5(8):e2225485. PubMed ID: 35947386 [TBL] [Abstract][Full Text] [Related]
12. Five-Year Adjuvant Endocrine Therapy Adherence Trajectories Among Women With Breast Cancer: A Nationwide French Study Using Administrative Data. Lailler G; Memoli V; Le Bihan Benjamin C; Ben Diane MK; Lauzier S; Mancini J; Bousquet PJ; Bouhnik AD Clin Breast Cancer; 2021 Aug; 21(4):e415-e426. PubMed ID: 33745868 [TBL] [Abstract][Full Text] [Related]
13. Association of Endocrine Therapy Initiation Timeliness With Adherence and Continuation in Low-Income Women With Breast Cancer. Sood N; Liu Y; Lian M; Greever-Rice T; Lucht J; Schmaltz C; Colditz GA JAMA Netw Open; 2022 Aug; 5(8):e2225345. PubMed ID: 35921108 [TBL] [Abstract][Full Text] [Related]
14. Personal and clinical social support and adherence to adjuvant endocrine therapy among hormone receptor-positive breast cancer patients in an integrated health care system. Kroenke CH; Hershman DL; Gomez SL; Adams SR; Eldridge EH; Kwan ML; Ergas IJ; Kubo A; Kushi LH Breast Cancer Res Treat; 2018 Aug; 170(3):623-631. PubMed ID: 29671113 [TBL] [Abstract][Full Text] [Related]
15. The Association Between Out-of-Pocket Costs and Adherence to Adjuvant Endocrine Therapy Among Newly Diagnosed Breast Cancer Patients. Farias AJ; Hansen RN; Zeliadt SB; Ornelas IJ; Li CI; Thompson B Am J Clin Oncol; 2018 Jul; 41(7):708-715. PubMed ID: 27893470 [TBL] [Abstract][Full Text] [Related]
16. Adjuvant therapy use among Appalachian breast cancer survivors. Tan X; Marshall VD; Anderson RT; Donohoe J; Camacho F; Balkrishnan R Medicine (Baltimore); 2015 Jul; 94(26):e1071. PubMed ID: 26131828 [TBL] [Abstract][Full Text] [Related]
17. Disparities in Initial Oral Antidiabetic Medication Adherence Among Veterans with Incident Diabetes. Gatwood JD; Chisholm-Burns M; Davis R; Thomas F; Potukuchi P; Hung A; Kovesdy CP J Manag Care Spec Pharm; 2018 Apr; 24(4):379-389. PubMed ID: 29578849 [TBL] [Abstract][Full Text] [Related]
18. Are breast cancer patients with suboptimal adherence to cardiovascular treatment more likely to discontinue adjuvant endocrine therapy? Competing risk survival analysis in a nationwide cohort of postmenopausal women. Artignan J; Capmas P; Panjo H; Constantinou P; Pelletier-Fleury N BMC Med; 2023 Nov; 21(1):463. PubMed ID: 38001491 [TBL] [Abstract][Full Text] [Related]
19. Adherence trajectories of adjuvant endocrine therapy in the five years after its initiation among women with non-metastatic breast cancer: a cohort study using administrative databases. Lambert-Côté L; Bouhnik AD; Bendiane MK; Bérenger C; Mondor M; Huiart L; Lauzier S Breast Cancer Res Treat; 2020 Apr; 180(3):777-790. PubMed ID: 32086655 [TBL] [Abstract][Full Text] [Related]
20. Factors Associated with Endocrine Therapy Non-Adherence in Breast Cancer Survivors. Spencer JC; Reeve BB; Troester MA; Wheeler SB Psychooncology; 2020 Apr; 29(4):647-654. PubMed ID: 32048400 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]